Creative Medical Technology's Olastrocel Therapy Receives INN Approval

Creative Medical Technology Marks a Milestone with INN Approval

PHOENIX — Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a pioneering clinical-stage biotechnology firm focused on regenerative medicine, has recently reached a significant milestone. The World Health Organization (WHO) has officially recognized "olastrocel" as the International Non-Proprietary Name (INN) for the active cellular substance in CELZ-201, their flagship allogeneic cell therapy also referred to as AlloStem®.

Understanding the Importance of INN

The INN serves as a universally accepted, unique identifier for therapeutic substances. This designation is crucial for regulators, clinicians, and researchers, providing clarity throughout the therapeutic product's lifecycle—from development to commercialization. Timothy Warbington, President and CEO of Creative Medical, emphasized that this approval marks an important development in their journey, asserting its significance for global adoption and scalability of their innovative therapies.

The Vision Behind Olastrocel

Warbington expressed that having a WHO-recognized INN strengthens Creative Medical's position and adds credibility to their therapeutic approach. He noted, "This unified identity is vital as we push forward with our clinical strategies targeting major health concerns including chronic lower back pain, diabetes, and immune-mediated diseases—all of which present enormous market opportunities."

Accelerating Development with FDA Designations

Creative Medical Technologies isn't stopping at the INN approval. The company is also actively pursuing its FDA Fast Track designation specifically for the treatment of degenerative disc disease. This dual recognition amplifies their presence in an arena demanding innovative solutions for long-standing conditions.

What Olastrocel (CELZ-201) is All About

Olastrocel represents an allogeneic cellular therapeutic candidate sourced from perinatal tissue, showcasing the cutting-edge advancements under the AlloStem® platform. It aims to provide effective treatment options for various medical conditions, including:

• Chronic lower back pain and degenerative disc disease (DDD)
• New-onset Type 1 diabetes
• Biodefense-related health issues

About Creative Medical Technology Holdings, Inc.

This innovative company is on a mission to tackle unmet medical needs through its extensive pipeline of cell and immune therapies, particularly in neurology, urology, orthopedics, and autoimmune diseases. Armed with proprietary regenerative platforms and a solid regulatory strategy, Creative Medical leverages scientific expertise to accelerate the development of breakthrough therapies.

Contact Information for Inquiries

For more details about their groundbreaking work and vision, Creative Medical Technology Holdings can be contacted at:

Email: IR@CreativeMedicalTechnology.com

Website: www.creativemedicaltechnology.com

Frequently Asked Questions

What is the significance of the INN approval for Creative Medical?

The INN approval signifies global recognition and harmonization for the therapeutic compound, facilitating its development and market entry.

What conditions does Olastrocel aim to treat?

Olastrocel is designed to treat chronic lower back pain, Type 1 diabetes, and biodefense-related conditions among other targeted therapies.

Why is the FDA Fast Track designation important?

The FDA Fast Track designation accelerates the development and review of therapies that address unmet medical needs in serious conditions, paving the way for quicker patient access.

How does Creative Medical Technology ensure regulatory compliance?

Creative Medical employs a robust regulatory strategy combined with scientific innovations to navigate the complexities of regulatory landscapes across different markets.

Where can I learn more about Creative Medical Technology's initiatives?

More information about their groundbreaking research and therapies can be found on their official website at www.creativemedicaltechnology.com.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.